Literature DB >> 8612653

Assessing anthracycline cardiotoxicity in the 1990s.

I Carrió1, M Estorch, A López-Pousa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8612653     DOI： 10.1007/bf01247361

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


× No keyword cloud information.
  46 in total

1.  Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer.

Authors:  M Estorch; I Carrió; L Berná; C Martínez-Duncker; C Alonso; J R Germá; B Ojeda
Journal:  J Nucl Med       Date:  1990-12       Impact factor: 10.057

2.  Adriamycin, congestive cardiomyopathy, and metaiodobenzylguanidine.

Authors:  A Strashun
Journal:  J Nucl Med       Date:  1992-02       Impact factor: 10.057

3.  Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.

Authors:  L J Steinherz; T Graham; R Hurwitz; H M Sondheimer; R G Schwartz; E M Shaffer; G Sandor; L Benson; R Williams
Journal:  Pediatrics       Date:  1992-05       Impact factor: 7.124

4.  A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.

Authors:  M S Ewer; M K Ali; B Mackay; S Wallace; M Valdivieso; S S Legha; R S Benjamin; T P Haynie
Journal:  J Clin Oncol       Date:  1984-02       Impact factor: 44.544

5.  I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity.

Authors:  R A Valdés Olmos; W W ten Bokkel Huinink; J C Greve; C A Hoefnagel
Journal:  Clin Nucl Med       Date:  1992-03       Impact factor: 7.794

6.  Pilot study of cardiac function after treatment of childhood Wilms' tumor with doxorubicin.

Authors:  J Blatt; C DeLaat; F J Fricker; J E Janosky
Journal:  Pediatr Hematol Oncol       Date:  1995 Jan-Feb       Impact factor: 1.969

7.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

8.  Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies.

Authors:  G Bacci; P Picci; S Ferrari; R Casadei; A Brach Del Prever; A Tienghi; A Mancini
Journal:  J Chemother       Date:  1993-08       Impact factor: 1.714

9.  Ewing's sarcoma: long-term follow-up in 49 patients treated from 1967 to 1989.

Authors:  H Mameghan; R J Fisher; D O'Gorman-Hughes; E H Bates; R L Huckstep; J Mameghan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-02-15       Impact factor: 7.038

10.  Monitoring for anthracycline cardiotoxicity.

Authors:  S E Lipshultz; S P Sanders; A M Goorin; J P Krischer; S E Sallan; S D Colan
Journal:  Pediatrics       Date:  1994-03       Impact factor: 7.124
View more
  2 in total

1.  Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure.

Authors:  B Schaadt; H Kelbaek
Journal:  J Nucl Cardiol       Date:  1997 Nov-Dec       Impact factor: 5.952

2.  Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.

Authors:  I Shureiqi; S B Cantor; S M Lippman; D E Brenner; M E Chernew; A M Fendrick
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.